Atara biotherapeutics presents new magnetization transfer ratio imaging data and two-year clinical data from the open label extension of ata188 for progressive multiple sclerosis at ectrims 2021

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced new translational data based on magnetization transfer ratio (mtr) and updated phase 1 open-label extension (ole) clinical data in patients with progressive multiple sclerosis (ms) treated with ata188
ATRA Ratings Summary
ATRA Quant Ranking